[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,73,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100593468","a-multicenter-prospective-blood-collection-study-in-a-kidney-transplant-population-100593468",false,"NCT07006831","A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population","Accept cfDNA","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Is 18 years of age or older at enrollment\n3. Had a kidney transplant prior to enrollment\n4. Is having an indication (for cause) biopsy as determined by clinician\n5. retrospective leftover samples are available from the kidney donor(s).\n\nExclusion Criteria:\n\n1. Is pregnant\n2. Had a blood transfusion within the past 4 weeks\n3. Had a transplant from an identical (monozygotic) twin\n4. Had transplants of multiple organs from the same donor (eg, kidney and liver transplant).\n5. Had transplants of more than 2 organs from different donors (eg, recipient of a third kidney transplant)\n6. Had a transplant of hematopoietic stem cells (eg, bone marrow) or tissue (eg, heart valve)","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.",[24,25,26,27,28,29],"Kidney Disease","Kidney Transplant","Transplant Recipient","Renal Function","Cell-free DNA","NGS","RECRUITING","2025-12-15",{"date":33,"type":34},"2025-12-17","ACTUAL",{"date":36,"type":34},"2025-11-14",{"date":38,"type":20},"2027-03",{"name":40,"class":41},"Devyser Inc.","INDUSTRY",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100597202","association-between-qmaxegfr-ratio-and-luts-severity-in-men-over-40-100597202","NCT07055425","Association Between Qmax\u002FeGFR Ratio and LUTS Severity in Men Over 40","The Role of Qmax\u002FeGFR Ratio in Assessing Symptom Severity and QoL in Men Over 40 With LUTS","Inclusion Criteria:\n\n* Male patients aged 40 years or older presenting with lower urinary tract symptoms (LUTS)\n* Able to provide informed consent\n* Willing and able to undergo uroflowmetry and blood testing\n* Able to complete the IPSS questionnaire, including the QoL item\n* Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fmin\u002F1.73m²\n\nExclusion Criteria:\n\n* History of urological surgery (e.g., prostatectomy, bladder surgery)\n* Diagnosed or suspected prostate cancer\n* Active urinary tract infection (based on clinical symptoms or urinalysis)\n* Neurological conditions affecting bladder function (e.g., Parkinson's disease, spinal cord injury)\n* Presence of an indwelling urinary catheter at enrollment\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Inability to perform uroflowmetry or complete clinical evaluations","MALE","40 Years",{"count":53,"type":20},100,"This study will look at how well a measure called the Qmax\u002FeGFR ratio is related to the severity of urination problems in men over the age of 40. Qmax is a test that shows how fast a person can urinate, and eGFR is a number that reflects kidney function. Men who have urinary symptoms will be asked to do a urine flow test, a blood test, and fill out a questionnaire about their symptoms and quality of life. We will study if there is a link between the Qmax\u002FeGFR ratio and how severe their symptoms are. The results may help doctors better understand how kidney and urinary function are related in men with these problems.",[56,57,58,27,59],"Lower Urinary Tract Symptom","Voiding Dysfunction","Male Urological Health","Benign Prostate Obstruction (BPO)",[56,59,58,57,61],"Aging Male","NOT_YET_RECRUITING","2025-08-30",{"date":65,"type":34},"2025-09-05",{"date":67,"type":20},"2025-09-01",{"date":69,"type":20},"2026-05-01",{"name":71,"class":72},"Marmara University","OTHER",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100580524","evaluation-of-the-effect-of-finerenone-on-renal-function-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-100580524","NCT06838416","Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease","Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Prospective, Single-Arm, Multicenter Clinical Study","KSD-01","Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes according to the 1999 WHO criteria\n* Aged ≥18 years\n* UACR ≥30 mg\u002Fg and eGFR ≥30 ml\u002Fmin\u002F1.73 m² sustained for over 3 months\n* Stable ARB\u002FACEI treatment for ≥4 weeks prior to enrollment\n* Willing to sign a written informed consent and comply with the study protocol\n\nExclusion Criteria:\n\n* Chronic kidney disease diagnosed before Type 2 diabetes\n* Serum potassium \\>4.8 mmol\u002FL\n* Ineffective blood pressure control at screening (systolic BP ≥160 mmHg and\u002For diastolic BP ≥100 mmHg, average of three measurements in the supine position)\n* HbA1c \\>9%\n* Acute urinary tract infection or conditions affecting urine tests\n* Primary or secondary adrenal insufficiency\n* Use of mineralocorticoid receptor antagonists\n* Use of medications with clear effects on urine protein and eGFR within 4 weeks (except kininogenase)\n* Use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone, carbamazepine)\n* ALT or AST \\>2.5 × ULN, total bilirubin (TBIL) \\>2 × ULN\n* Use of systemic glucocorticoids for more than 7 days within 12 weeks prior to screening, or use of systemic glucocorticoids (intravenous\u002Foral or intra - articular) or need for systemic immunosuppressive treatment within the past 14 days\n* Any organ system cancer within the past 5 years, whether treated or untreated\n* Known pregnancy (positive pregnancy test), breastfeeding, recent plans for conception, or not using adequate contraception\n* Participation in other interventional clinical trials within 3 months prior to screening",{"count":82,"type":20},300,"1 Year","Research Objectives To evaluate the impact of finerenone on renal function, diabetic complications, and safety in patients with Type 2 diabetes and chronic kidney disease.\n\nStudy Design Type: Prospective, single-arm, multicenter clinical trial. Sample Size: 300 patients. Intervention: Finerenone added to existing treatment regimen (10-20 mg once daily, dose adjusted based on eGFR), for 48 weeks.\n\nData Collection Time Points: Baseline, 4 weeks, 12 weeks, 24 weeks, 36 weeks, and 48 weeks.\n\nPrimary Endpoint: Change in urine albumin-to-creatinine ratio (UACR). Secondary Endpoints: Changes in eGFR, 24-hour urine protein, serum uric acid, retinopathy markers, pulse wave velocity (PWV), ankle-brachial index (ABI), etc.\n\nSafety Endpoints: Changes in serum potassium, sodium, and blood pressure.",[86,87,27],"Type 2 Diabetes Mellitus","Chronic Kidney Disease","2025-04-01",{"date":90,"type":34},"2025-04-04",{"date":92,"type":34},"2023-11-17",{"date":94,"type":20},"2026-12-31",{"name":96,"class":72},"Second Affiliated Hospital of Soochow University",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":4,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":97},"100501782","urinary-creatinine-excretion-time-in-the-neonatal-period-100501782","NCT05813730","Urinary Creatinine Excretion Time in the Neonatal Period","Definition of Urinary Creatinine Excretion Time in the Neonatal Period, in Full Term Newborns : a Prospective Monocentric Study","C-Rex","Inclusion Criteria:\n\n* All full-term newborns (37WA or more)\n* From a physiological and spontaneous pregnancy\n* Good neonatal adaptation (Apgar 7 at 5 minutes of life)\n* Eutrophic (weight \\> 10th percentile and \\\u003C 90th percentile)\n\nExclusion Criteria:\n\n* Newborns for whom no urine sample is interpretable\n* Those with a significant clinical-biological anomaly\n* Neonates with hemodynamic disorders such as low blood pressure (median \\\u003C gestational age) or hypovolemia (shock, signs of dehydration, need for volume expansion) during the first 3 days of life",true,"3 Days",{"count":109,"type":20},40,"INTERVENTIONAL",[112],"NA","Newborn's renal function is difficult to assess and its physiology during the first days of life is still incompletely known. Studies suggest that the newborn almost completely reabsorbs creatinine during the first 48 to 72 hours of life, while at the same time it continues to produce its own creatinine. Therefore, the initial stock of creatinine at birth still increases through this production and the non or weak clearance. A better knowledge of renal physiopathology in newborns would allow to improve the therapeutic management of the infants, particularly in case of potential nephrotoxicity. No study has attempted to assess the increase in urinary creatinine excretion in neonates from a given time.\n\nObjectives: To show when urinary creatinine excretion in newborns is efficient. Results: this study mightr show an inflection point in urinary creatinine excretion illustrating the postnatal age when renal function becomes efficient.",[27],[116,27,117],"Newborn","Physiology","2025-02-18",{"date":120,"type":34},"2025-02-19",{"date":122,"type":34},"2024-10-30",{"date":124,"type":20},"2025-12",{"name":126,"class":72},"Central Hospital, Nancy, France"]